According to CN5S (2021), the diagnosis of IDH wild-type glioblastoma is based on the presence of EGFR amplification or TERT promoter mutation, or the combined gain of the whole chromosome 7 and the loss of whole chromosome 10 (+7/−10) [3,81,82,83]. The gene discussed is IDH2; the disease is glioblastoma.